Disc Medicine (IRON) Q2 Loss Widens 109%

Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company advancing treatments for hematologic diseases, released its second quarter 2025 earnings on August 7, 2025. Reflecting investments in critical clinical programs, the period showed progress on pipeline milestones but highlighted accelerating losses associated with ramping up for late-stage trials and potential commercialization. Source: Analyst estimates for the quarter provided by FactSet. Disc Medicine is focused on discovering and developing therapies for patients suffering from serious blood disorders. The company does not yet sell any commercial products; instead, it invests heavily in the clinical testing of new molecules.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool